Sabrina Serani

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 emerging as a potential biomarker.

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for development of this antibody-drug conjugate.

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual disease rates in relapsed CLL.

The EFTISARC-NEO trial of eftilagimod alfa with radiotherapy and pembrolizumab in resectable soft tissue sarcoma achieved its primary end point.

In ASCENT-03, sacituzumab govitecan significantly extended progression-free survival in metastatic triple-negative breast cancer not eligible for PD-(L)1 inhibitors.

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by bispecific antibody therapy.

In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients.

Statin use in CLL/SLL patients showed improved survival regardless of treatment, suggesting repurposing potential for this accessible drug.

In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study that supports it.

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients with mantle cell lymphoma.

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and potentially enabling more patients to access vital therapies.

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and health care providers.

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do support a positive benefit-risk ratio for patients with smoldering multiple myeloma.

In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.

The phase 3 IDeate-Esophageal01 study of ifinatamab deruxtecan has dosed its first patient with esophageal squamous cell carcinoma.

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.

First-line cemiplimab showed improved survival vs chemotherapy in advanced NSCLC with brain metastases and PD-L1 ≥50% in EMPOWER-Lung 1.

BCB-276 has earned regenerative medicine advanced therapy designation from the FDA in diffuse intrinsic pontine glioma, an incurable pediatric tumor.

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of advanced anal cancer.

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end point of progression-free survival.

Christopher Schenewerk, MD, discussed his history with alcohol abuse and how he works to break down the taboo of substance abuse among medical professionals.

Adding pertuzumab to standard of care improved survival by 17% in patients with early-stage HER2-positive breast cancer.

THE001, a thermosensitive doxorubicin liposome for soft tissue sarcomas, received FDA orphan drug designation, offering development benefits.

The FDA has cleared investigational new drug applications and handed out fast track designations. Plus, data shows promise for novel therapies in hard-to-treat cancers.

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug conjugate for solid tumors.

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of patients with neuroblastoma.

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast cancer, according to DESTINY-Breast11 data.

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been accepted by the FDA.